BSX

Boston Scientific Corp
NYSEHEALTHCAREMEDICAL DEVICES

Key Statistics

Market Cap
$63.65B
P/E Ratio
17.78
EPS
$2.47
Beta
0.57
52W High
$105.65
52W Low
$42.20
50-Day MA
$46.89
200-Day MA
$63.20
Dividend Yield
—
Profit Margin
17.50%
Forward P/E
13.23
PEG Ratio
0.63

About Boston Scientific Corp

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)$21.00B
Gross Profit (TTM)$14.53B
EBITDA$5.71B
Operating Margin22.90%
Return on Equity15.30%
Return on Assets6.19%
Revenue/Share (TTM)$14.19
Book Value$17.23
Price-to-Book2.59
Price-to-Sales (TTM)3.03
EV/Revenue3.655
EV/EBITDA13.62
Quarterly Earnings Growth (YoY)15.10%
Quarterly Revenue Growth (YoY)7.50%
Shares Outstanding$1.45B
Float$1.44B
% Insiders0.25%
% Institutions94.73%

Historical Volatility

HV 10-Day
33.93%
HV 20-Day
39.37%
HV 30-Day
40.27%
HV 60-Day
36.94%
HV Rank
63.1%

Volatility is currently contracting

Analyst Ratings

Consensus ($61.00 target)
8
Strong Buy
18
Buy
5
Hold

Latest News

Boston Scientific: A Great Company At A Deeply Discounted Price (Rating Upgrade)

Boston Scientific is upgraded to 'Strong Buy' as market overreaction creates an attractive entry point for long-term investors. BSX trades at a forward P/E of 13.1, well below its historical average, despite robust profitability and solid Q2 2026 results. Growth headwinds from WATCHMAN and electrophysiology are offset by strong Interventional Cardiology and Vascular Therapies momentum.

Seeking Alpha9/15/2026Positive
Boston Scientific: $43 Finally Prices In A Bad 2026

Boston Scientific's cyberattack will hurt third-quarter results, but manufacturing and shipping recovered quickly enough that much of the missing revenue should be delayed rather than lost. I am more concerned about WATCHMAN and U.S. electrophysiology, which had already slowed before the attack, and the additional debt coming with Penumbra. BSX shares now trade near 13 times the company's withdrawn earnings forecast. I estimate fair value at $55, leaving enough room for a Buy without assuming that growth immediately returns.

Seeking Alpha9/11/2026Negative
Is Boston Scientific (BSX) a Buy as Wall Street Analysts Look Optimistic?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Zacks Investment Research9/11/2026Positive
Boston Scientific Restores Key Operations After Cyberattack

The company said products are moving through its distribution network at or above normal levels as the Marlborough, Mass., company works to fulfill customer orders, reduce backlogs and accelerate the delivery of products.

WSJ9/10/2026Positive

Turn research into an automated options-selling system

Tiblio connects your broker and runs your put-and-call-writing strategy for you — on BSX and any ticker you trade — then tracks every position and per-strategy win rate.

See how it works

More HEALTHCARE Stocks

Data last updated: 9/26/2026